401.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$392.24
Aprire:
$388.68
Volume 24 ore:
1.78M
Relative Volume:
1.78
Capitalizzazione di mercato:
$52.39B
Reddito:
$2.46B
Utile/perdita netta:
$-319.09M
Rapporto P/E:
-162.67
EPS:
-2.47
Flusso di cassa netto:
$-52.09M
1 W Prestazione:
+22.20%
1M Prestazione:
+24.76%
6M Prestazione:
+48.10%
1 anno Prestazione:
+49.58%
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-30 | Ripresa | Raymond James | Outperform |
2025-07-21 | Iniziato | Truist | Buy |
2025-03-31 | Iniziato | Redburn Atlantic | Buy |
2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
2024-02-16 | Downgrade | Goldman | Buy → Neutral |
2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
2023-09-29 | Iniziato | Raymond James | Outperform |
2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2023-04-26 | Iniziato | SMBC Nikko | Neutral |
2023-03-21 | Iniziato | Bernstein | Outperform |
2023-01-18 | Iniziato | Canaccord Genuity | Buy |
2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
2022-06-07 | Iniziato | William Blair | Outperform |
2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2022-03-01 | Iniziato | Citigroup | Buy |
2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
2021-02-12 | Reiterato | H.C. Wainwright | Buy |
2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2020-09-30 | Ripresa | Berenberg | Hold |
2020-09-08 | Iniziato | Citigroup | Buy |
2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
2020-04-24 | Ripresa | Evercore ISI | Outperform |
2020-03-19 | Iniziato | Berenberg | Buy |
2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
2019-11-20 | Iniziato | Oppenheimer | Outperform |
2019-11-13 | Iniziato | BofA/Merrill | Buy |
2019-05-23 | Ripresa | Goldman | Neutral |
2019-04-12 | Iniziato | Evercore ISI | Outperform |
2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2019-01-23 | Iniziato | UBS | Neutral |
2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
2018-08-13 | Reiterato | Stifel | Buy |
2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
2018-05-04 | Reiterato | Stifel | Hold |
2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga
Why Alnylam Pharmaceuticals (ALNY) Is Up 23.7% After Raising 2025 Revenue Outlook on AMVUTTRA Growth - simplywall.st
When is Alnylam Pharmaceuticals Inc. stock expected to show significant growthDiscover top stock picks for aggressive growth - jammulinksnews.com
How does Alnylam Pharmaceuticals Inc. compare to its industry peersUnmatched market performance - jammulinksnews.com
What are the latest earnings results for Alnylam Pharmaceuticals Inc.Free Capital Efficiency Planning - jammulinksnews.com
Does Alnylam Pharmaceuticals Inc. stock perform well during market downturnsCapitalize on momentum-driven investment opportunities - jammulinksnews.com
How does Alnylam Pharmaceuticals Inc. generate profit in a changing economyConsistently superior profits - jammulinksnews.com
What makes Alnylam Pharmaceuticals Inc. stock price move sharplyUnlock powerful stock screening tools today - jammulinksnews.com
How volatile is Alnylam Pharmaceuticals Inc. stock compared to the marketCapitalize on strong market momentum - jammulinksnews.com
Alnylam Pharmaceuticals Inc. Stock Analysis and ForecastMaximize gains with strategic stock entries - jammulinksnews.com
What are the technical indicators suggesting about Alnylam Pharmaceuticals Inc.Discover the fastest growing stocks today - jammulinksnews.com
Published on: 2025-08-03 13:52:50 - jammulinksnews.com
What catalysts could drive Alnylam Pharmaceuticals Inc. stock higher in 2025Exceptional risk-adjusted gains - jammulinksnews.com
Alnylam Pharmaceuticals' Q2 2025: Unraveling Key Contradictions in AMVUTTRA's Market Strategy and Patient Access - AInvest
Is it the right time to buy Alnylam Pharmaceuticals Inc. stockBreakout Stocks Signals Backed By Experts - jammulinksnews.com
BMO Capital Reaffirms Buy Rating on Alnylam Pharma with $450 Price Target - AInvest
Alnylam Pharmaceuticals Sees Strong Sales of Rare Disease Drug, Raises Revenue Guidance - AInvest
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance - AOL.com
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
Alnylam projects $2.65B–$2.8B 2025 revenue following AMVUTTRA ATTR-CM launch momentum - MSN
Why Is Alnylam Stock Gaining Friday?Alnylam Pharmaceuticals (NASDAQ:ALNY) - Benzinga
Alnylam soars past $50B market cap - The Business Journals
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up - TradingView
Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - simplywall.st
Alnylam Pharmaceuticals, Inc to Host Earnings Call - ACCESS Newswire
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates - MSN
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q2 2025 Earnings Call Transcript - Insider Monkey
Narrow-Moat Alnylam's Strong Launch of Amvuttra for ATTR-CM Drives Growth; Pipeline Makes Progress - Morningstar
Alnylam Pharmaceuticals Lifts Revenue Outlook After Earnings Beat - Finimize
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress - BioSpace
Alnylam Pharmaceuticals 2025 Q2 Earnings Misses Targets as Net Loss Widens 292% - AInvest
Alnylam Pharmaceuticals Inc (ALNY) Q2 2025 Earnings Call Highlig - GuruFocus
Alnylam Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT In - GuruFocus
Alnylam: Q2 Earnings Snapshot - Norwalk Hour
Alnylam Soars 15.43% on $1.31B Trade Volume Surge as TTR Revenues Jump 64% and Raised 2025 Outlook - AInvest
Amvuttra's stellar performance pushes Alnylam's guidance, stock higher - FirstWord Pharma
Alnylam Pharmaceuticals Surges 15.43% On Strong Technical Breakout - AInvest
Novartis wins FDA label update for Alnylam-partnered cholesterol drug - Seeking Alpha
Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches - insights.citeline.com
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast - inkl
Alnylam's Amvuttra: A Game-Changer in ATTR-CM and a Catalyst for Biotech Growth - AInvest
Alnylam: Amvuttra Is Just Getting Started (NASDAQ:ALNY) - Seeking Alpha
Alnylam reaches new highs on strong sales of closely watched rare disease drug - BioPharma Dive
Earnings call transcript: Alnylam’s Q2 2025 results boost stock by 18% - Investing.com Nigeria
Alnylam Pharmaceuticals soars 17.6% as Q2 results crush estimates - Investing.com
Alnylam Pharmaceuticals soars 17.6% as Q2 results crush estimates By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals Surpasses Wall Street Expectations in Q2News and Statistics - IndexBox
Alnylam jumps on full year revenue guidance raise (ALNY) - Seeking Alpha
Alnylam Q2 2025 slides: ATTR-CM launch drives 64% revenue growth, guidance raised - Investing.com Canada
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):